Citeline Podcasts

In accepting Scrip’s Lifetime Achievement Award, Ovid Therapeutics’ CEO called on pharma to show responsible leadership and live up to its potential to do good for society.

Brian Yang and Dexter Yan discuss the FDA approval of Chinese PD-1, Sanofi BioMap AI deal, Third quarter earnings and Biden-Xi Summit and US-China regulatory dialogue.

In this podcast, Medtech Insight speaks to Andy Molnar, CEO of the digital therapeutics alliance; Joel Morse, CEO and co-founder of Curavit and Owen McCarthy, CEO and co-founder of MedRhythyms. The trio discuss the current situation surrounding digital therapeutics, and where they believe they are headed in the coming years.

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with Abbott’s head of Lingo Biowearables and top executives at Twin Health. Reed Miller provides an update on J&J MedTech’s launch of the Ottava soft-tissue robotic surgery system and Barnaby Pickering talks about his recent interview with Leo Grady, former CEO of Paige AI, to talk about his new start-up Jona.

Medtech Insight articles addressing topics discussed in this episode:

Can Digital Twin Technology Help Beat Chronic Disease? Twin Health Is Getting Users Hooked, And Off Their Meds

https://medtech.citeline.com/MT148407/Can-Digital-Twin-Technology-Help-Beat-Chronic-Disease-Twin-Health-Is-Getting-Users-Hooked-And-Off-Their-Meds

Abbott’s Metabolic Biowearable Gets ‘Extremely Positive’ UK Reception; Next Up, US Filing

https://medtech.citeline.com/MT148365/Abbotts-Metabolic-Biowearable-Gets-Extremely-Positive-UK-Reception-Next-Up-US-Filing

After Two-Year Delay, J&J Plans To Start Trial Ottava Surgical Robot In 2024

https://medtech.citeline.com/MT148422/After-TwoYear-Delay-JJ-Plans-To-Start-Trial-Ottava-Surgical-Robot-In-2024

Leo Grady’s Jona Hopes To Repair Microbiome Testing’s Murky Reputation

https://medtech.citeline.com/MT148403/Leo-Gradys-Jona-Hopes-To-Repair-Microbiome-Testings-Murky-Reputation

Investing In Digital: Slow And Steady May Win This Race

https://invivo.citeline.com/IV148596/Investing-In-Digital-Slow-And-Steady-May-Win-This-Race

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: AstraZeneca CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?

https://scrip.citeline.com/SC149388/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporters and editors discuss US FDA Principal Deputy Commissioner Janet Woodcock’s legacy as her retirement approaches (:42), the stance of the FDA’s oncology division on confirming benefit after an accelerated approval (16:59), and why formal meetings between the agency and sponsors cannot be recorded (36:51).

More On These Topics From The Pink Sheet

With Woodcock’s Retirement, US FDA Loses A Renaissance Woman: https://pink.citeline.com/PS149368/With-Woodcocks-Retirement-US-FDA-Loses-A-Renaissance-Woman

Confirmatory Trial Plan For Acrotech’s Folotyn, Beleodaq Needs Rethinking, FDA Panel Says: https://pink.citeline.com/PS149361/Confirmatory-Trial-Plan-For-Acrotechs-Folotyn-Beleodaq-Needs-Rethinking-FDA-Panel-Says

FDA Panel To Consider Strategies For Timely Completion Of Accelerated Approval Confirmatory Trials: https://pink.citeline.com/PS149353/FDA-Panel-To-Consider-Strategies-For-Timely-Completion-Of-Accelerated-Approval-Confirmatory-Trials

Accelerated Approval: US FDA Writing Guidance On What ‘Ongoing’ Means For Confirmatory Trials: https://pink.citeline.com/PS149359/Accelerated-Approval-US-FDA-Writing-Guidance-On-What-Ongoing-Means-For-Confirmatory-Trials

Accelerated Approval: Acrotech’s Confirmatory Trial For Folotyn, Beleodaq More Than A Decade Behind Schedule: https://pink.citeline.com/PS149342/Accelerated-Approval-Acrotechs-Confirmatory-Trial-For-Folotyn-Beleodaq-More-Than-A-Decade-Behind-Schedule

Minutes Matter: Why The US FDA Refuses To Record Formal Meetings: https://pink.citeline.com/PS149310/Minutes-Matter-Why-The-US-FDA-Refuses-To-Record-Formal-Meetings

Syngene’s MD & CEO, Jonathan Hunt, in an interview with Scrip, dissects trends and opportunities in the CRDMO segment as US biotechs slow their burn rate amid a funding squeeze while other large and medium-sized biopharma firms seek to rebalance their supply chain. The Indian firm’s ability to add value in the development and manufacture of ADCs and also its partnership with Amgen are some of the other topics the ex-AstraZeneca executive discusses.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: US approval for Lilly’s obesity drug; a look at the future of the obesity market; BMS’s ADC deal; Roche’s MS plans; and one Chinese firm’s CAR-T plans.

https://scrip.citeline.com/SC149349/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporter and editors discuss the FTC’s challenges of Orange Book patents (:35), DTC promotion practices as part of acquisition due diligence (12:39), and how Intarcia’s advisory committee decision appeal could play out (19:06).

More On These Topics From The Pink Sheet

In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap: https://pink.citeline.com/PS149316/In-Swift-Challenge-To-Orange-Book-Patent-Listings-Federal-Trade-Commission-Fills-FDA-Ministerial-Gap

Rx Ad/Promo Practices Should Be Part Of Acquisition Due Diligence, DoJ Official Says: https://pink.citeline.com/PS149309/Rx-AdPromo-Practices-Should-Be-Part-Of-Acquisition-Due-Diligence-DoJ-Official-Says

Intarcia Appeals Advisory Committee On Diabetes Drug-Device Combo, Claiming ‘Misrepresentation’: https://pink.citeline.com/PS149311/Intarcia-Appeals-Advisory-Committee-On-Diabetes-DrugDevice-Combo-Claiming-Misrepresentation

In this episode, HBW Insight speaks to Simon-Kucher & Partners about the latest trends in preventative consumer health. Partner Christian Rebholz and senior director Lorenzo Eandi explain the findings from the company’s recently published Better Health Report, which reached out to almost 3,000 consumers from across the world. We take a deeper dive into Brazil, where consumers are spending more on than average on preventative health, and Germany, where consumers are spending less but are turning to digital tools thanks to government support. We also find out what consumer health companies can do to respond to a growing awareness of mental health, especially among women and the younger generation.